Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -58.05% is 460% below its 3-year average of 16.12%, near the high end of its 3-year range (-3491.02%–100.00%).
91.65% above its 12-month average of -695.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
-58.05%
GROSS MARGIN AVG TTM
-695.00%
GROSS MARGIN AVG 3Y
16.12%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+91.65%
CURRENT VS 3Y AVG
-460.00%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-240.29%
vs the sector median at left
Prime Medicine, Inc.
Market Cap
$647.51M
Gross Margin
-58.05%
TTM Avg
-695.00%
3Y Avg
16.12%
5Y Avg
0.00%
Market Cap
$656.86M
Gross Margin
15.69%
TTM Avg
15.20%
3Y Avg
15.20%
5Y Avg
15.20%
Market Cap
$658.11M
Gross Margin
78.85%
TTM Avg
82.67%
3Y Avg
82.58%
5Y Avg
83.02%
Market Cap
$661.68M
Gross Margin
100.27%
TTM Avg
50.13%
3Y Avg
25.07%
5Y Avg
10.71%
Market Cap
$661.38M
Gross Margin
91.05%
TTM Avg
-190849.07%
3Y Avg
-96132.87%
5Y Avg
-64176.88%
Market Cap
$632.51M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$679.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
33.33%
Market Cap
$680.46M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | $647.51M | -58.05% | -695.00% | 16.12% | 0.00% |
| Starling Oncology, Inc. (STLN)vs › | $656.86M | 15.69% | 15.20% | 15.20% | 15.20% |
| MiMedx Group, Inc. (MDXG)vs › | $658.11M | 78.85% | 82.67% | 82.58% | 83.02% |
| Helus Pharma Inc. (HELP)vs › | $661.68M | 100.27% | 50.13% | 25.07% | 10.71% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $661.38M | 91.05% | -190849.07% | -96132.87% | -64176.88% |
| Annexon, Inc. (ANNX)vs › | $667.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aura Biosciences, Inc. (AURA)vs › | $632.51M | 0.00% | 0.00% | 0.00% | 0.00% |
| Solid Biosciences Inc. (SLDB)vs › | $679.79M | 0.00% | 0.00% | 25.00% | 33.33% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $680.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $626.92M | 84.52% | 76.56% | 85.05% | 87.20% |
Gross Margin
-58.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -116.82% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | -3491.02% |
| 2025-06-30 | -67.17% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | -122.50% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2019-12-31 | 0.00% |
